Nanoscribe, the pioneer and market leader in high-precision additive manufacturing, strengthens its strategic position by entering the Cellink group. Cellink was founded in 2016 for commercializing the world’s first universal bioink. The publicly listed company has consistently expanded its portfolio into a bioconvergence company offering solutions for bioprinting, multiomics, cell line development and diagnostics. Nanoscribe will continue developing high-precision additive manufacturing solutions as part of the Cellink’s business area bioprinting.

The life science industry is currently going through a very exciting transformation where many processes and technologies are being miniaturized to increase throughput and reduce cost, where price of reagents is a major bottle neck for sequencing. One example is the sample preparation steps for single cell genomics applications.

With Nanoscribe’s microfabrication technologies, the Cellink group stays competitive in this transformation and aims to miniaturize devices for a wide range of applications, resulting in internal capabilities to further expand its consumables offering across all business areas.

The Cellink Group will then be the world’s first life science company with internal two-photon polymerization (2PP) additive manufacturing capabilities. Nanoscribe’s 2PP technology enables bioprinting of vascular microenvironments at subcellular scale, suitable for cell studies and lab-on-a-chip applications, which is expected to contribute to the groups’ product development, yielding additional recurring revenue through fabrication of implants, microneedles, microporous membranes, and consumables for omics applications.

There are several strong synergies by combining Cellink’s cutting-edge macro structural bioprinting technology with Nanoscribe’s micro structural bioprinting technology for more realistic tissue architecture, including vascularization, cell supports. The 2PP technology will enable a cross-functional adoption within all three business areas and enhance consumables product development and offerings of the Cellink group. 

“With Nanoscribe’s state-of-the-art 2PP technology, we will complement our product portfolio and offer a wider range of products to our amazing customers. We are combining our strong, purpose driven growth agenda with trailblazing bioconverging technologies for the sake of improving health all around the world,” emphasizes Erik Gatenholm, CEO of Cellink. (Source: Nanoscribe)